A detailed history of Redmile Group, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 6,427,462 shares of ANNX stock, worth $46.8 Million. This represents 2.05% of its overall portfolio holdings.

Number of Shares
6,427,462
Previous 5,503,190 16.8%
Holding current value
$46.8 Million
Previous $39.5 Million 20.18%
% of portfolio
2.05%
Previous 1.56%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.33 - $6.79 $4 Million - $6.28 Million
924,272 Added 16.8%
6,427,462 $31.5 Million
Q4 2023

Feb 14, 2024

BUY
$1.63 - $4.63 $3.26 Million - $9.26 Million
2,000,000 Added 57.09%
5,503,190 $25 Million
Q2 2022

Aug 15, 2022

BUY
$2.11 - $4.06 $633,576 - $1.22 Million
300,273 Added 9.37%
3,503,190 $13.2 Million
Q1 2022

May 16, 2022

SELL
$2.73 - $11.94 $70,980 - $310,440
-26,000 Reduced 0.81%
3,202,917 $8.74 Million
Q4 2021

Feb 14, 2022

SELL
$11.49 - $22.0 $1.38 Million - $2.65 Million
-120,268 Reduced 3.59%
3,228,917 $37.1 Million
Q3 2021

Nov 15, 2021

SELL
$16.35 - $23.4 $1.24 Million - $1.77 Million
-75,853 Reduced 2.21%
3,349,185 $62.3 Million
Q2 2021

Aug 16, 2021

SELL
$17.81 - $27.48 $601,835 - $928,604
-33,792 Reduced 0.98%
3,425,038 $77.1 Million
Q1 2021

May 17, 2021

BUY
$22.0 - $35.01 $237,600 - $378,108
10,800 Added 0.31%
3,458,830 $96.3 Million
Q4 2020

Feb 16, 2021

BUY
$20.81 - $30.55 $122,945 - $180,489
5,908 Added 0.17%
3,448,030 $86.3 Million
Q3 2020

Nov 16, 2020

BUY
$17.5 - $30.23 $60.2 Million - $104 Million
3,442,122 New
3,442,122 $104 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $347M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.